Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease

David L. Hwang, Shiao Ping Huang, Wuu Shyang Lan, Phillip Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Insulin-like growth factor-binding protein-1 (IGFBP-1) is one of six soluble binding proteins that regulate the actions of the insulin-like growth factors (IGFs). Liver is the major source of IGFBP-1 in non-pregnant humans. In normal physiology, IGFBP-1 transcription is potently inhibited by insulin and serum levels are limited by a rapid clearance rate. Elevated levels of IGFBP-1 in liver disease have been attributed to insulin resistance; however, the relationships between these analytes have not been defined. We studied insulin, proinsulin and IGFBP-1 in normal subjects (NL, N = 47, 43 ± 12 yr), cirrhosis (CIR, N = 29, 54 ± 14 yr), hepatocellular carcinoma (HCC, N = 42, 61 ± 11 yr), and other liver tumors (TUM, N = 8, 60 ± 17 yr). All three analytes were significantly increased in liver disease (mean±SEM; p-values relative to normals): IGFBP-1 (NL 24 ± 4 ng/ml; CIR 235 ± 53, p < 0.0001: HCC 505 ± 105, p< 0.0001: TUM 118 ± 36, p< 0.0001), insulin (NL 72 ± 4 pM; CIR 261 ± 62, p < 0.0002; HCC 180 ± 25, p < 0.0001: TUM 189 ± 58, p < 0.0001), proinsulin (NL 6.5 ± 0.7 pM; CIR 36.8 ± 7.7, p < 0.0001; HCC 26.2 ± 3.8, p < 0.0001; TUM 32.1 ± 9.7, p < 0.0001). The ratio of proinsulin to insulin was also significantly elevated in liver disease. A typical curvilinear inverse relationship of insulin and IGFBP-1 was observed, but was shifted several fold higher for the liver disease groups. Our results demonstrate that insulin and proinsulin are elevated in liver disease. However, these elevations are paradoxically accompanied by elevated IGFBP-1 levels, indicating disruption of normal regulatory mechanisms. IGFBP-1 is postulated to play a dynamic role in metabolic substrate utilization via regulation of free IGF. Therefore, inappropriate elevation of IGFBP-1 could play an important role in the metabolic disturbances associated with liver disease.

Original languageEnglish (US)
Pages (from-to)316-321
Number of pages6
JournalGrowth Hormone and IGF Research
Volume13
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Proinsulin
Liver Diseases
Insulin
Somatomedins
Liver
Insulin Resistance
Hepatocellular Carcinoma
Carrier Proteins
Fibrosis

Keywords

  • Cirrhosis
  • Hepatocellular carcinoma
  • IGFBP-1
  • Insulin
  • Liver disease
  • Proinsulin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease. / Hwang, David L.; Huang, Shiao Ping; Lan, Wuu Shyang; Lee, Phillip.

In: Growth Hormone and IGF Research, Vol. 13, No. 6, 12.2003, p. 316-321.

Research output: Contribution to journalArticle

Hwang, David L. ; Huang, Shiao Ping ; Lan, Wuu Shyang ; Lee, Phillip. / Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease. In: Growth Hormone and IGF Research. 2003 ; Vol. 13, No. 6. pp. 316-321.
@article{1dd2a33bd97e42a18aa00a77c2fba679,
title = "Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease",
abstract = "Insulin-like growth factor-binding protein-1 (IGFBP-1) is one of six soluble binding proteins that regulate the actions of the insulin-like growth factors (IGFs). Liver is the major source of IGFBP-1 in non-pregnant humans. In normal physiology, IGFBP-1 transcription is potently inhibited by insulin and serum levels are limited by a rapid clearance rate. Elevated levels of IGFBP-1 in liver disease have been attributed to insulin resistance; however, the relationships between these analytes have not been defined. We studied insulin, proinsulin and IGFBP-1 in normal subjects (NL, N = 47, 43 ± 12 yr), cirrhosis (CIR, N = 29, 54 ± 14 yr), hepatocellular carcinoma (HCC, N = 42, 61 ± 11 yr), and other liver tumors (TUM, N = 8, 60 ± 17 yr). All three analytes were significantly increased in liver disease (mean±SEM; p-values relative to normals): IGFBP-1 (NL 24 ± 4 ng/ml; CIR 235 ± 53, p < 0.0001: HCC 505 ± 105, p< 0.0001: TUM 118 ± 36, p< 0.0001), insulin (NL 72 ± 4 pM; CIR 261 ± 62, p < 0.0002; HCC 180 ± 25, p < 0.0001: TUM 189 ± 58, p < 0.0001), proinsulin (NL 6.5 ± 0.7 pM; CIR 36.8 ± 7.7, p < 0.0001; HCC 26.2 ± 3.8, p < 0.0001; TUM 32.1 ± 9.7, p < 0.0001). The ratio of proinsulin to insulin was also significantly elevated in liver disease. A typical curvilinear inverse relationship of insulin and IGFBP-1 was observed, but was shifted several fold higher for the liver disease groups. Our results demonstrate that insulin and proinsulin are elevated in liver disease. However, these elevations are paradoxically accompanied by elevated IGFBP-1 levels, indicating disruption of normal regulatory mechanisms. IGFBP-1 is postulated to play a dynamic role in metabolic substrate utilization via regulation of free IGF. Therefore, inappropriate elevation of IGFBP-1 could play an important role in the metabolic disturbances associated with liver disease.",
keywords = "Cirrhosis, Hepatocellular carcinoma, IGFBP-1, Insulin, Liver disease, Proinsulin",
author = "Hwang, {David L.} and Huang, {Shiao Ping} and Lan, {Wuu Shyang} and Phillip Lee",
year = "2003",
month = "12",
doi = "10.1016/S1096-6374(03)00042-X",
language = "English (US)",
volume = "13",
pages = "316--321",
journal = "Endocrinology and Metabolism",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease

AU - Hwang, David L.

AU - Huang, Shiao Ping

AU - Lan, Wuu Shyang

AU - Lee, Phillip

PY - 2003/12

Y1 - 2003/12

N2 - Insulin-like growth factor-binding protein-1 (IGFBP-1) is one of six soluble binding proteins that regulate the actions of the insulin-like growth factors (IGFs). Liver is the major source of IGFBP-1 in non-pregnant humans. In normal physiology, IGFBP-1 transcription is potently inhibited by insulin and serum levels are limited by a rapid clearance rate. Elevated levels of IGFBP-1 in liver disease have been attributed to insulin resistance; however, the relationships between these analytes have not been defined. We studied insulin, proinsulin and IGFBP-1 in normal subjects (NL, N = 47, 43 ± 12 yr), cirrhosis (CIR, N = 29, 54 ± 14 yr), hepatocellular carcinoma (HCC, N = 42, 61 ± 11 yr), and other liver tumors (TUM, N = 8, 60 ± 17 yr). All three analytes were significantly increased in liver disease (mean±SEM; p-values relative to normals): IGFBP-1 (NL 24 ± 4 ng/ml; CIR 235 ± 53, p < 0.0001: HCC 505 ± 105, p< 0.0001: TUM 118 ± 36, p< 0.0001), insulin (NL 72 ± 4 pM; CIR 261 ± 62, p < 0.0002; HCC 180 ± 25, p < 0.0001: TUM 189 ± 58, p < 0.0001), proinsulin (NL 6.5 ± 0.7 pM; CIR 36.8 ± 7.7, p < 0.0001; HCC 26.2 ± 3.8, p < 0.0001; TUM 32.1 ± 9.7, p < 0.0001). The ratio of proinsulin to insulin was also significantly elevated in liver disease. A typical curvilinear inverse relationship of insulin and IGFBP-1 was observed, but was shifted several fold higher for the liver disease groups. Our results demonstrate that insulin and proinsulin are elevated in liver disease. However, these elevations are paradoxically accompanied by elevated IGFBP-1 levels, indicating disruption of normal regulatory mechanisms. IGFBP-1 is postulated to play a dynamic role in metabolic substrate utilization via regulation of free IGF. Therefore, inappropriate elevation of IGFBP-1 could play an important role in the metabolic disturbances associated with liver disease.

AB - Insulin-like growth factor-binding protein-1 (IGFBP-1) is one of six soluble binding proteins that regulate the actions of the insulin-like growth factors (IGFs). Liver is the major source of IGFBP-1 in non-pregnant humans. In normal physiology, IGFBP-1 transcription is potently inhibited by insulin and serum levels are limited by a rapid clearance rate. Elevated levels of IGFBP-1 in liver disease have been attributed to insulin resistance; however, the relationships between these analytes have not been defined. We studied insulin, proinsulin and IGFBP-1 in normal subjects (NL, N = 47, 43 ± 12 yr), cirrhosis (CIR, N = 29, 54 ± 14 yr), hepatocellular carcinoma (HCC, N = 42, 61 ± 11 yr), and other liver tumors (TUM, N = 8, 60 ± 17 yr). All three analytes were significantly increased in liver disease (mean±SEM; p-values relative to normals): IGFBP-1 (NL 24 ± 4 ng/ml; CIR 235 ± 53, p < 0.0001: HCC 505 ± 105, p< 0.0001: TUM 118 ± 36, p< 0.0001), insulin (NL 72 ± 4 pM; CIR 261 ± 62, p < 0.0002; HCC 180 ± 25, p < 0.0001: TUM 189 ± 58, p < 0.0001), proinsulin (NL 6.5 ± 0.7 pM; CIR 36.8 ± 7.7, p < 0.0001; HCC 26.2 ± 3.8, p < 0.0001; TUM 32.1 ± 9.7, p < 0.0001). The ratio of proinsulin to insulin was also significantly elevated in liver disease. A typical curvilinear inverse relationship of insulin and IGFBP-1 was observed, but was shifted several fold higher for the liver disease groups. Our results demonstrate that insulin and proinsulin are elevated in liver disease. However, these elevations are paradoxically accompanied by elevated IGFBP-1 levels, indicating disruption of normal regulatory mechanisms. IGFBP-1 is postulated to play a dynamic role in metabolic substrate utilization via regulation of free IGF. Therefore, inappropriate elevation of IGFBP-1 could play an important role in the metabolic disturbances associated with liver disease.

KW - Cirrhosis

KW - Hepatocellular carcinoma

KW - IGFBP-1

KW - Insulin

KW - Liver disease

KW - Proinsulin

UR - http://www.scopus.com/inward/record.url?scp=0345602043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345602043&partnerID=8YFLogxK

U2 - 10.1016/S1096-6374(03)00042-X

DO - 10.1016/S1096-6374(03)00042-X

M3 - Article

VL - 13

SP - 316

EP - 321

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 1096-6374

IS - 6

ER -